KRAS and cancer: A higher proportion of variant than wild-type KRAS tumors were seen for stage IV for YO (1025 patients [66.3%] vs 1421 patients [61.9%]; P = .03) and LO (4358 patients [59.6%] vs 5416 patients [51.5%]; P < .001) cancers (Table).